Latest Breaking News On - Maghsoud dariani - Page 1 : vimarsana.com

Lobe Sciences Announces Additional Details Regarding the Acquisition of Altemia(TM) & Company

Lobe Sciences Announces Additional Details Regarding the Acquisition of Altemia(TM) & Company
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomBritish columbiaFred sancilioPhilipj youngMaghsoud darianiAlex sancilioCanadian securities exchangeBritish columbia securities commissionRare disease drug development companyClearway globalLobe sciencesNatural emulsion technologyInternational license agreement with double digit royaltyAltemia companyBritish columbia newsfile corp

Lobe Sciences Ltd : Lobe Sciences Announces Additional Details Regarding the Acquisition of Altemia & Company

Lobe Sciences Ltd : Lobe Sciences Announces Additional Details Regarding the Acquisition of Altemia & Company
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

British columbiaUnited statesUnited kingdomFred sancilioMaghsoud darianiPhilipj youngAlex sancilioCanadian securities exchangeBritish columbia newsfile corpLobe sciencesLobe sciences ltdRare disease drug development companyBritish columbia securities commissionInternational license agreement with double digit royaltyClearway globalAmerican biopharmaceutical company

Lobe Sciences new acquisition boosts rare disease drug portfolio

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) revealed that it has inked a share purchase agreement to acquire Altemia & Company LLC and all its assets,.

Philipj youngMaghsoud darianiFrederickd sancilioAltemia companyLobe sciences ltdSickle cell diseaseOrphan drugsPediatric priority review voucherLobe chief scientific officer maghsoud darianiPriority review voucher

Lobe Sciences Ltd : Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130

Vancouver, British Columbia (Newsfile Corp. - November 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering

United statesUnited kingdomBritish columbiaMaghsoud darianiPhilipj youngLobe sciences ltdClearway globalLobe sciencesBritish columbia newsfile corpNorth american biopharmaceuticalChief executive officerNew chemical entitieOrphan drug applicationPriority review voucher

Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130

Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomBritish columbiaMaghsoud darianiPhilipj youngLobe sciences ltdClearway globalLobe sciencesBritish columbia newsfile corpNorth american biopharmaceuticalChief executive officerNew chemical entitieOrphan drug applicationPriority review voucher